These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17162089)

  • 1. Activation of the mTOR signaling pathway in renal clear cell carcinoma.
    Robb VA; Karbowniczek M; Klein-Szanto AJ; Henske EP
    J Urol; 2007 Jan; 177(1):346-52. PubMed ID: 17162089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. mTOR and P70 S6 kinase expression in primary liver neoplasms.
    Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
    Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Morphoproteomic and molecular concomitants of an overexpressed and activated mTOR pathway in renal cell carcinomas.
    Lin F; Zhang PL; Yang XJ; Prichard JW; Lun M; Brown RE
    Ann Clin Lab Sci; 2006; 36(3):283-93. PubMed ID: 16951269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Frequent [corrected] hyperphosphorylation of ribosomal protein S6 [corrected] in lymphangioleiomyomatosis-associated angiomyolipomas.
    Robb VA; Astrinidis A; Henske EP
    Mod Pathol; 2006 Jun; 19(6):839-46. PubMed ID: 16575396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Critical and diverse involvement of Akt/mammalian target of rapamycin signaling in human lung carcinomas.
    Dobashi Y; Suzuki S; Matsubara H; Kimura M; Endo S; Ooi A
    Cancer; 2009 Jan; 115(1):107-18. PubMed ID: 19090006
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Activation of mTOR in renal cell carcinoma is due to increased phosphorylation rather than protein overexpression.
    Kruck S; Bedke J; Hennenlotter J; Ohneseit PA; Kuehs U; Senger E; Sievert KD; Stenzl A
    Oncol Rep; 2010 Jan; 23(1):159-63. PubMed ID: 19956876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phosphorylation of p70S6 kinase predicts overall survival in patients with clear margin-resected hepatocellular carcinoma.
    Baba HA; Wohlschlaeger J; Cicinnati VR; Hilgard P; Lang H; Sotiropoulos GC; Takeda A; Beckebaum S; Schmitz KJ
    Liver Int; 2009 Mar; 29(3):399-405. PubMed ID: 18492014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of the mammalian target of rapamycin pathway and the effect of rapamycin on target expression and cellular proliferation in osteosarcoma cells from dogs.
    Gordon IK; Ye F; Kent MS
    Am J Vet Res; 2008 Aug; 69(8):1079-84. PubMed ID: 18672974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Analysis of mTOR signaling by the small G-proteins, Rheb and RhebL1.
    Tee AR; Blenis J; Proud CG
    FEBS Lett; 2005 Aug; 579(21):4763-8. PubMed ID: 16098514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Morphoproteomic profile of mTOR, Ras/Raf kinase/ERK, and NF-kappaB pathways in human gastric adenocarcinoma.
    Feng W; Brown RE; Trung CD; Li W; Wang L; Khoury T; Alrawi S; Yao J; Xia K; Tan D
    Ann Clin Lab Sci; 2008; 38(3):195-209. PubMed ID: 18715846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation.
    Follo MY; Mongiorgi S; Bosi C; Cappellini A; Finelli C; Chiarini F; Papa V; Libra M; Martinelli G; Cocco L; Martelli AM
    Cancer Res; 2007 May; 67(9):4287-94. PubMed ID: 17483341
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Estradiol attenuates the focal cerebral ischemic injury through mTOR/p70S6 kinase signaling pathway.
    Koh PO; Cho JH; Won CK; Lee HJ; Sung JH; Kim MO
    Neurosci Lett; 2008 May; 436(1):62-6. PubMed ID: 18378082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An activated mTOR/p70S6K signaling pathway in esophageal squamous cell carcinoma cell lines and inhibition of the pathway by rapamycin and siRNA against mTOR.
    Hou G; Xue L; Lu Z; Fan T; Tian F; Xue Y
    Cancer Lett; 2007 Aug; 253(2):236-48. PubMed ID: 17360108
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting beta2-microglobulin mediated signaling as a novel therapeutic approach for human renal cell carcinoma.
    Nomura T; Huang WC; Seo S; Zhau HE; Mimata H; Chung LW
    J Urol; 2007 Jul; 178(1):292-300. PubMed ID: 17499801
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statin-dependent suppression of the Akt/mammalian target of rapamycin signaling cascade and programmed cell death 4 up-regulation in renal cell carcinoma.
    Woodard J; Sassano A; Hay N; Platanias LC
    Clin Cancer Res; 2008 Jul; 14(14):4640-9. PubMed ID: 18628479
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin-like growth factor-1 (IGF-1) and leucine activate pig myogenic satellite cells through mammalian target of rapamycin (mTOR) pathway.
    Han B; Tong J; Zhu MJ; Ma C; Du M
    Mol Reprod Dev; 2008 May; 75(5):810-7. PubMed ID: 18033679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Melatonin prevents ischemic brain injury through activation of the mTOR/p70S6 kinase signaling pathway.
    Koh PO
    Neurosci Lett; 2008 Oct; 444(1):74-8. PubMed ID: 18721861
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer.
    Nozawa H; Watanabe T; Nagawa H
    Cancer Lett; 2007 Jun; 251(1):105-13. PubMed ID: 17175097
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting mTOR in renal cell carcinoma.
    Hudes GR
    Cancer; 2009 May; 115(10 Suppl):2313-20. PubMed ID: 19402072
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mammalian target of rapamycin inhibitors in renal cell carcinoma: current status and future applications.
    Pantuck AJ; Thomas G; Belldegrun AS; Figlin RA
    Semin Oncol; 2006 Oct; 33(5):607-13. PubMed ID: 17045090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.